Neurogene Inc Dossier - Source-backed chat

Neurogene Inc

NGNENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $26.55Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $531.3M

Enterprise Value $418.8M

Shares Outstanding 22.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Neurogene Inc. is a highly promising clinical-stage biotechnology company advancing NGN-401, a potential best-in-class, one-time gene therapy for Rett syndrome. By utilizing its proprietary EXACT transgene regulation technology, Neurogene successfully delivers the full-length MECP2 gene while avoiding the overexpression toxicities that have historically plagued Rett syndrome gene therapies. The company has completed dosing in its pivotal Embolden registrational trial ahead of schedule, demonstrating strong demand and robust execution. Backed by a solid cash runway extending into Q1 2028, Neurogene is well-positioned to navigate key clinical and manufacturing milestones ahead of its anticipated topline data readout in H2 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$46.00

Mean target$81.71

High · most bullish analyst$180.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$16.0015%

The bear case is triggered by safety concerns, such as late-onset adverse events or a case of HLH at the 1E15 vg dose, which could lead to clinical holds or restrictive labeling. Alternatively, if the Embolden trial fails to meet the 33% minimum response rate or shows marginal efficacy, the BLA submission would be delayed or rejected, severely impacting the company's valuation and forcing dilutive capital raises.

Base CaseCentral scenario

$81.7160%

Matches the consensus mean

The base case assumes NGN-401 successfully meets its primary composite endpoint in the Embolden trial with a solid responder rate (e.g., 50%-60%), demonstrating clear therapeutic benefit over baseline. The safety profile remains favorable, allowing for a successful BLA submission in late 2027 or early 2028. The company initiates its PPQ campaign smoothly, and its cash runway remains sufficient to reach regulatory approval.

Bull CaseUpside scenario

$180.0025%

The bull case assumes NGN-401 demonstrates exceptional efficacy in the Embolden trial, significantly exceeding the 33% minimum responder threshold with an 80%+ CGI-I response rate, mirroring its early Phase 1/2 results. The safety profile remains pristine with zero cases of HLH at the 1E15 vg dose. Rapid BLA approval and a highly successful commercial launch, supported by early commercial-readiness activities and strong payor reimbursement, drive the stock to the high end of analyst expectations.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary EXACT technology solves the narrow therapeutic index of MECP2 expression, mitigating overexpression toxicity.
Successful completion of dosing in the Embolden registrational trial (25 participants) ahead of schedule, demonstrating high investigator and patient demand.
Strong cash position of $243.2 million (as of March 31, 2026) provides a comfortable runway into Q1 2028, covering pivotal readouts.
Encouraging interim Phase 1/2 data showing multidomain, durable functional gains across core clinical areas of Rett syndrome.

Key Investment Risks

Clinical and regulatory risks inherent to gene therapies, including potential late-onset safety events (e.g., HLH or hyperinflammation).
Execution risks associated with the upcoming Process Performance Qualification (PPQ) campaign and commercial-scale manufacturing scale-up.
Dependence on a single primary asset (NGN-401) for near-to-mid-term valuation.

Thesis Invalidation Triggers

Occurrence of severe, systemic safety events (such as HLH) at the therapeutic 1E15 vg dose level in the Embolden or Phase 1/2 trials.
Failure of the Embolden trial to achieve the pre-specified 33% minimum response rate (at least 8 of 24 ITT participants showing improvement).
Significant delays or failures in the PPQ manufacturing campaign, pushing back the BLA submission timeline.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.